Holen Sie sich die Stockscreener-App
1.24
36.08%
-0.70
Handel nachbörslich:
1.23
-0.01
-0.81%
Schlusskurs vom Vortag:
$1.94
Offen:
$1.48
24-Stunden-Volumen:
5.22M
Relative Volume:
10.53
Marktkapitalisierung:
$65.06M
Einnahmen:
$21.05M
Nettoeinkommen (Verlust:
$-89.22M
KGV:
-0.6927
EPS:
-1.79
Netto-Cashflow:
$-64.50M
1W Leistung:
-45.61%
1M Leistung:
-41.23%
6M Leistung:
-22.50%
1J Leistung:
-74.95%
1-Tages-Spanne:
$1.10
$1.48
1-Wochen-Bereich:
$1.10
$2.281
52-Wochen-Spanne:
$1.02
$6.225
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Firmenname
Tscan Therapeutics Inc
Sektor
Branche
Telefon
857-399-9500
Adresse
830 WINTER STREET, WALTHAM
Vergleichen Sie TCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.24 | 110.09M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-16 | Eingeleitet | BTIG Research | Buy |
| 2024-05-13 | Eingeleitet | Needham | Buy |
| 2023-06-22 | Eingeleitet | Wedbush | Outperform |
Tscan Therapeutics Inc Aktie (TCRX) Neueste Nachrichten
TScan to focus on heme program, cuts workforce by 30% amid FDA progress - Investing.com Nigeria
Tscan Therapeutics stock plunges after pausing solid tumor trial enrollment By Investing.com - Investing.com UK
Tscan Therapeutics stock plunges after pausing solid tumor trial enrollment - Investing.com
Trend analysis for TScan Therapeutics Inc. this weekWatch List & Target Return Focused Picks - newser.com
Reversal indicators forming on TScan Therapeutics Inc. stockMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com
How TScan Therapeutics Inc. stock performs in rate cut cyclesRecession Risk & Low Risk Entry Point Tips - newser.com
What technical models suggest about TScan Therapeutics Inc.’s comebackExit Point & Weekly Watchlist of Top Performers - newser.com
Using data filters to optimize entry into TScan Therapeutics Inc.Weekly Risk Report & High Yield Equity Trading Tips - newser.com
TScan Therapeutics Shifts Focus to Hematologic Malignancies - TipRanks
How TScan Therapeutics Inc. stock reacts to global recession fearsDividend Hike & Expert-Curated Trade Recommendations - newser.com
TScan Therapeutics Announces Positive Phase I Meeting with FDA, Strategic Workforce Reduction, and Focus on Hematologic Malignancies - Quiver Quantitative
TScan Therapeutics Announces 30% Workforce Reduction, Cash Runway Extension - TradingView
TScan Therapeutics expects $2.3 million one-time charge for severance during 3 months ended Dec 31 - MarketScreener
TScan Therapeutics Expects $2.3 Million One-Time Charge For Severance During 3 Months Ended Dec 31 - TradingView
TScan Therapeutics (NASDAQ: TCRX) extends cash runway to H2 2027; cuts workforce about 30% - Stock Titan
Best data tools to analyze TScan Therapeutics Inc. stockJuly 2025 EndofMonth & Weekly Setup with High ROI Potential - newser.com
Technical signs of recovery in TScan Therapeutics Inc.Chart Signals & Stock Timing and Entry Methods - newser.com
Should you wait for a breakout in TScan Therapeutics Inc.Portfolio Risk Summary & Community Driven Trade Alerts - newser.com
Is TScan Therapeutics Inc. stock positioned well for digital economy2025 Winners & Losers & Free Community Supported Trade Ideas - newser.com
Applying chart zones and confluence areas to TScan Therapeutics Inc.July 2025 Big Picture & Low Drawdown Investment Ideas - newser.com
Is TScan Therapeutics Inc. building a consolidation base2025 Year in Review & Stock Timing and Entry Methods - newser.com
Can swing trading help recover from TScan Therapeutics Inc. lossesTrade Risk Summary & Comprehensive Market Scan Insights - newser.com
Can TScan Therapeutics Inc. stock maintain growth trajectoryEarnings Growth Report & Community Trade Idea Sharing - newser.com
Is TScan Therapeutics Inc. still worth holding after the dipBull Run & Technical Pattern Recognition Alerts - newser.com
How TScan Therapeutics Inc. stock performs in high volatility marketsJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com
Applying sector rotation models to TScan Therapeutics Inc.Weekly Trade Recap & AI Based Buy/Sell Signal Reports - newser.com
Finanzdaten der Tscan Therapeutics Inc-Aktie (TCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):